Quality of Life and Insulin Therapy in Type 2 Diabetes Mellitus

Insulin

Volumn 3, Issue 1, 2008, Pages 31-36

  Funnell, Martha M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

barriers; insulin; quality of life; type 2 diabetes mellitus

Indexed keywords

INSULIN; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

AMBULATORY CARE; ARTICLE; BEDTIME DOSAGE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES EDUCATION; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HUMAN; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MEDLINE; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; WEIGHT GAIN;

EID: 40449125241     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(08)80009-7     Document Type: Article

References (41)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853 published correction appears in
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 354 (1999) 602
3. Ohkubo U., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complica-tions in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
4. Saaddine J., Cadwell B., Gregg E., et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 144 (2006) 465
5. Peyrot M., Rubin R., Lauritzen T., et al., International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
6. Wallace T., and Matthews D. Poor glycaemic control in type 2 diabetes: A conspiracy of disease, suboptimal therapy and attitude. QJM 93 (2000) 369-374
7. de Sonnaville J., Snoek F., Colly L., et al. Well-being and symp-toms in relation to insulin therapy in type 2 diabetes. Diabetes Care 21 (1998) 919-924
8. Haque M., Emerson S., Dennison C., et al. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Capetown. S Afr Med J 95 (2005) 798-802
9. Hunt L., Valenzuela M., and Pugh J. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 20 (1997) 292-298
10. Wolfenbuttal B., Drossaert C., and Visser A. Determinants of injecting insulin in elderly patients with type 2 diabetes mellitus. Patient Educ Couns 22 (1993) 117-125
11. Rubin R., and Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 15 (1999) 205-218
12. Boyer J., and Earp J. The development of an instrument for assess-ing the quality of life for people with diabetes. Med Care 35 (1997) 440-453
13. Wexler D., Grant R., Wittenberg E., et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia 49 (2006) 1489-1497
14. Brown D., Balluz L., Giles W., et al., Behavioral Risk Factor Surveillance System (BRFSS). Diabetes mellitus and health-related quality of life among older adults. Findings from the behavioral risk factor surveillance system (BRFSS). Diabetes Res Clin Pract 65 (2004) 105-115
15. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by inten-sive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22 (1999) 1125-1136
16. Redekop W., Koopmanschap M., Stolk R., et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 25 (2002) 458-463
17. Davis R., Morrissey M., Peters J., et al. Impact of hypoglycae-mia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 21 (2005) 1477-1483
18. Davis T., Clifford R., Davis W., and Fremantle Diabetes Study. Effects of insulin therapy on quality of life in type 2 dia-betes mellitus: The Fremantle Diabetes Study. Diabetes Res Clin Pract 52 (2001) 63-71
19. de Grauw W., van de Lisdonk E., van Gerwen W., et al. In-sulin therapy in poorly controlled type 2 diabetic patients: Does it affect quality of life?. Br J Gen Pract 51 (2001) 527-532
20. Pibernik-Okanovic M., Szabo S., and Metelko Z. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 14 (1998) 201-207
21. Fischer J., McLaughlin T., Loza L., et al. The impact of insulin glargine on clinical and humanistic outcomes in patients with uncontrolled on other insulin and oral agents: An office-based naturalistic study. Curr Med Res Opin 20 (2004) 1703-1710
22. Vinik A., and Zhang Q. Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30 (2007) 795-800 pub-lished correction appears in
23. Vinik A., and Zhang Q. Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30 (2007) 1684
24. Houlden R., Ross S., Harris S., et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the manage-ment of type 2 diabetes: The Canadian INSIGHT study. Diabetes Res Clin Pract 78 (2007) 254-258
25. Menard J., Payette H., Dubuc N., et al. Quality of life in type 2 diabetes patients under intensive multitherapy. Diabetes Metab 33 (2007) 54-60
26. Hornquist J., Wikby A., Andersson P., and Dufva A. Insulin-pen treatment, quality of life and metabolic control: Retrospective intra-group evaluations. Diabetes Res Clin Pract 10 (1990) 221-230
27. Stockl K., Ory C., Vanderplas A., et al. An evaluation of patient pref-erence for an alternative insulin delivery system compared to stan-dard vial and syringe. Curr Med Res Opin 23 (2007) 133-146
28. Summers K., Szeinbach S., and Lennox S. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 26 (2004) 1498-1505
29. Korytkowski M., Bell D., Jacobsen C., Suwannasari R., and Flexpen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conven-tional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 25 (2003) 2836-2848
30. Testa M., and Simonson D. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care 30 (2007) 1399-1405
31. Herman W., Ilag L., Johnson S., et al. A clinical trial of con-tinuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28 (2005) 1568-1573
32. Polonsky W., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care 28 (2005) 2543-2545
33. Polonsky W., and Jackson R. What's so tough about taking insu-lin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes 22 (2004) 147-150
34. Hayes R., Bowman L., Monahan P., et al. Understanding dia-betes medications from the perspective of patients with type 2 diabetes: Prerequisite to medication concordance. Diabetes Educ 32 (2006) 404-414
35. Mollema E., Snoek F., Pouwer F., et al. Diabetes fear of inject-ing and self-testing questionnaire: A psychometric evaluation. Diabetes Care 23 (2000) 765-769
36. Funnell M., Kruger D., and Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ 30 (2004) 274-280
37. Bech P., Gudex C., and Johansen S. The WHO (Ten) Well-Being Index: Validation in diabetes. Psychother Psychosom 65 (1996) 183-190
38. Polonsky W., Anderson B., Lohrer P., et al. Assessment of diabetes-related distress. Diabetes Care 18 (1995) 754-760
39. Anderson R., and Funnell M. Diabetes Concerns Assessment Form 2005. Accessed (December 24, 2007). http://www.med.umich.edu/mdrtc/education
40. Garg S., Zisser H., Schwartz S., et al. Improvement in glycemic ex-cursions with a transcutaneous real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care 29 (2006) 44-50
41. Bailey T., Zisser H., and Garg S. Reduction in hemoglobin A1C with real-time continuous glucose monitoring: Results from a 12-week observational study. Diabetes Technol Ther 9 (2007) 203-210